Glucose transporter type 1 deficiency syndrome: clinical aspects, diagnosis, and treatment.
Gabriel M VeneruzzoMariana A LoosMarisa ArmenoCristina Noemi AlonsoRoberto H CaraballoPublished in: Archivos argentinos de pediatria (2022)
Glucose transporter type 1 deficiency with a typical onset is a genetic disorder associated with the SLC2A1 gene. Usually appears during the first years of life with severe developmental delay, drugresistant epilepsy, and movement disorders. Diagnosis is suspected based on clinical manifestations and a low glucose level in cerebrospinal fluid,and should be confirmed by the molecular genetic study of the SLC2A1 gene. As it is a rare disease with variable clinical expression, early diagnosis is often challenging for the healthcare team. Nevertheless, this is important because early implementation of ketogenic therapy will lead to control of the clinical manifestations and a better long-term prognosis. Here we review the glucose transporter type 1 deficiency syndrome focusing on its clinical, biochemical, molecular, and therapeutic characteristics.
Keyphrases
- healthcare
- genome wide
- blood glucose
- copy number
- cerebrospinal fluid
- primary care
- poor prognosis
- case report
- replacement therapy
- gene expression
- quality improvement
- stem cells
- early onset
- metabolic syndrome
- long non coding rna
- cell therapy
- skeletal muscle
- social media
- genome wide identification
- health information
- drug induced